ClinicalTrials.gg
CompletedNCT01071083RESTOREUpdated Sep 19, 2013Results posted

Treatment Interruption of Natalizumab

A Phase 2 interventional study of natalizumab and interferon beta 1-a in Relapsing Remitting Multiple Sclerosis, sponsored by Biogen. Completed at 33 sites in 3 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2013-09-19.

Sponsored by Biogen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
175
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing natalizumab in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, 1 under way, none of them phase 3. Natalizumab · Multiple Sclerosis, Relapsing-Remitting.

Enrollment
9th of 21
175 · median 110
Started
2010
with 2 others
Phase 2
4 of 21
none open now
Registered
10th of 21
by date
Lead sponsor
18 of 21
Biogen

Among the 21 studies testing natalizumab in Multiple Sclerosis, Relapsing-Remitting, this one is the 9th largest by enrollment, is one of 3 that started in 2010, is one of 4 in phase 2, and was the 10th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

None of the 21 studies testing natalizumab in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →

About natalizumab

Natalizumab: first FDA approval 2004 (TYSABRI), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies testing natalizumab in Multiple Sclerosis, Relapsing-Remitting as a file.
02

Study summary

This is a randomized, rater blinded trial in patients who interrupt treatment with natalizumab with or without being treated with other immunomodulatory drugs, or continue treatment with natalizumab.

The main purpose of this study is to find out the following, when participants stop taking natalizumab for 24 weeks:

  • when MS symptoms return, and
  • if other drugs for MS may help control MS symptoms during the natalizumab-interruption period.

This study will also explore how quickly the effects of natalizumab return after resuming natalizumab dosing.

03

Conditions studied

  • Relapsing Remitting Multiple Sclerosis

Keywords

  • MS
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Major criteria include:

  • A diagnosis of a relapsing form of MS
  • Treatment with natalizumab according to locally approved prescribing information
  • Other protocol defined inclusion/exclusion criteria may apply
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
175 participants (actual)

Study arms

  • Active comparator
    natalizumab

    Drug: natalizumab

  • Placebo comparator
    IV placebo

    Other: IV placebo

  • Active comparator
    interferon β-1a, glatiramer acetate, or methylprednisolone

    Drug: interferon beta 1-a · Drug: methylprednisolone · Drug: glatiramer acetate

Interventions

06

What researchers measure

Primary outcomes

  1. Time Course to Return of Radiological and/or Clinical Evidence of Multiple Sclerosis Activity, as Measured by the Percentage of Subjects Who Met Magnetic Resonance Imaging (MRI) and/or Clinical Relapse Rescue Criteria.

    Rescue criteria were: 1) central reader MRI finding of 1 new gadolinium-enhancing (Gd+) lesion of \>0.8 cubic centimeters in volume or 2 or more Gd+ lesions of any size 2) clinical relapse. Clinical relapse was new or recurrent neurological symptoms not associated with fever or infection, lasting at least 24 hours, as defined by: an increase of ≥1 grade in ≥2 functional scales of the Expanded Disability Status Scale (EDSS); an increase of ≥2 grades in 1 functional scale of the EDSS; or an increase of \>0.5 in EDSS if the previous EDSS was ≤5.5, or ≥0.5 if the previous EDSS was \>5.5

    Time frame: 28 Weeks

Secondary outcomes

  1. Time Course to Return of Radiological Activity, as Measured by the Percentage of Subjects Who Met Magnetic Resonance Imaging (MRI) Rescue Criteria.

    MRI rescue criteria were the presence of 1 new gadolinium-enhancing (Gd+) lesion of \>0.8 cubic centimeters in volume or 2 or more Gd+ lesions of any size, according to the central MRI reader.

    Time frame: 28 Weeks

07

Results

Posted Jan 30, 2013

Participant flow

Date of first treatment: 31 March 2010. Date of study completion: 02 November 2011.

Participant flow — Overall Study
MilestoneIntravenous PlaceboNatalizumabInterferon β-1aGlatiramer AcetateMethylprednisolone
Started4245171754
Completed3543121546
Not completed72528
Withdrew: Adverse event10101
Withdrew: Withdrawal by subject30203
Withdrew: Physician decision10011
Withdrew: Early rescue10001
Withdrew: Subject moved01000
Withdrew: Images not usable (motion)01000
Withdrew: Did not meet eligibility criteria00111
Withdrew: Did not want per protocol treatment00101
Withdrew: Subject refused to continue10000

Outcome measures

PrimaryTime Course to Return of Radiological and/or Clinical Evidence of Multiple Sclerosis Activity, as Measured by the Percentage of Subjects Who Met Magnetic Resonance Imaging (MRI) and/or Clinical Relapse Rescue Criteria.

Rescue criteria were: 1) central reader MRI finding of 1 new gadolinium-enhancing (Gd+) lesion of \>0.8 cubic centimeters in volume or 2 or more Gd+ lesions of any size 2) clinical relapse. Clinical relapse was new or recurrent neurological symptoms not associated with fever or infection, lasting at least 24 hours, as defined by: an increase of ≥1 grade in ≥2 functional scales of the Expanded Disability Status Scale (EDSS); an increase of ≥2 grades in 1 functional scale of the EDSS; or an increase of \>0.5 in EDSS if the previous EDSS was ≤5.5, or ≥0.5 if the previous EDSS was \>5.5

Time frame:
28 Weeks
Reported as:
Number · Percentage of subjects meeting criteria
Time Course to Return of Radiological and/or Clinical Evidence of Multiple Sclerosis Activity, as Measured by the Percentage of Subjects Who Met Magnetic Resonance Imaging (MRI) and/or Clinical Relapse Rescue Criteria.
Percentage of subjects meeting criteriaNatalizumabIntravenous PlaceboInterferon β-1aGlatiramer AcetateMethylprednisolone
Time Course to Return of Radiological and/or Clinical Evidence of Multiple Sclerosis Activity, as Measured by the Percentage of Subjects Who Met Magnetic Resonance Imaging (MRI) and/or Clinical Relapse Rescue Criteria.4.760.528.653.354.8
SecondaryTime Course to Return of Radiological Activity, as Measured by the Percentage of Subjects Who Met Magnetic Resonance Imaging (MRI) Rescue Criteria.

MRI rescue criteria were the presence of 1 new gadolinium-enhancing (Gd+) lesion of \>0.8 cubic centimeters in volume or 2 or more Gd+ lesions of any size, according to the central MRI reader.

Time frame:
28 Weeks
Reported as:
Number · Percentage of subjects meeting criteria
Time Course to Return of Radiological Activity, as Measured by the Percentage of Subjects Who Met Magnetic Resonance Imaging (MRI) Rescue Criteria.
Percentage of subjects meeting criteriaNatalizumabIntravenous PlaceboInterferon β-1aGlatiramer AcetateMethylprednisolone
Time Course to Return of Radiological Activity, as Measured by the Percentage of Subjects Who Met Magnetic Resonance Imaging (MRI) Rescue Criteria.0.052.58.349.746.1

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Intravenous Placebo———
Natalizumab———
Interferon β-1a———
Glatiramer Acetate———
Methylprednisolone———
Most frequent serious events
Most frequent serious events
EventIntravenous PlaceboNatalizumabInterferon β-1aGlatiramer AcetateMethylprednisolone
Multiple Sclerosis RelapseNervous system disorders0/420/450/171/170/54
SyncopeNervous system disorders0/420/451/170/170/54
PresyncopeNervous system disorders0/420/451/170/170/54
Multiple SclerosisNervous system disorders1/420/450/170/170/54
Chest PainGeneral disorders0/421/450/170/170/54
Brain AbscessInfections and infestations0/420/450/170/171/54
Most frequent other events
Showing 10 of 76
Most frequent other events
EventIntravenous PlaceboNatalizumabInterferon β-1aGlatiramer AcetateMethylprednisolone
INFLUENZA LIKE ILLNESSGeneral disorders0/420/455/171/170/54
NASOPHARYNGITISInfections and infestations5/4211/454/171/175/54
MULTIPLE SCLEROSIS RELAPSENervous system disorders8/422/454/174/1711/54
HEADACHENervous system disorders3/428/451/171/173/54
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations6/423/450/173/176/54
FATIGUEGeneral disorders6/422/451/172/172/54
URINARY TRACT INFECTIONInfections and infestations5/421/452/171/172/54
MUSCLE SPASMSMusculoskeletal and connective tissue disorders0/420/452/171/170/54
POST LUMBAR PUNCTURE SYNDROMEInjury, poisoning and procedural complications1/420/452/170/172/54
PAIN IN EXTREMITYMusculoskeletal and connective tissue disorders1/423/450/172/171/54

Baseline characteristics

Age Continuous
Age Continuous(Years)NatalizumabIntravenous PlaceboInterferon β-1aGlatiramer AcetateMethylprednisoloneTotal
Mean41.2 ± 9.7040.0 ± 10.3645.1 ± 9.9244.1 ± 7.8540.1 ± 9.9641.2 ± 9.85
Sex: Female, Male
Sex: Female, Male(Participants)NatalizumabIntravenous PlaceboInterferon β-1aGlatiramer AcetateMethylprednisoloneTotal
Female3731141439135
Male811331540
08

Study locations

33 sites
  • Research Site
    Cullman, Alabama 35058, United States
  • Research Site
    San Francisco, California 94117, United States
  • Research Site
    Fort Collins, Colorado, United States
  • Research Site
    Pompano Beach, Florida 33060, United States
  • Research Site
    Atlanta, Georgia 30309, United States
  • Research Site
    Atlanta, Georgia 30327, United States
  • Research Site
    Chicago, Illinois 60612, United States
  • Research Site
    Lake Barrington, Illinois 60010, United States
  • Research Site
    Des Moines, Iowa 50314, United States
  • Research Site
    Boston, Massachusetts 2135, United States
  • Research Site
    Boston, Massachusetts 2215, United States
  • Research Site
    Buffalo, New York 14203, United States
  • Research Site
    Latham, New York 12110, United States
  • Research Site
    Patchogue, New York 11772, United States
  • Research Site
    Charlotte, North Carolina 28207, United States
  • Research Site
    Raleigh, North Carolina 27607, United States
  • Research Site
    Cleveland, Ohio 44195, United States
  • Research Site
    Uniontown, Ohio, United States
  • Research Site
    Salt Lake City, Utah 84103, United States
  • Research Site
    Seattle, Washington 98111, United States
  • Research Site
    Freiburg, Baden-Wuerttemberg 79106, Germany
  • Research Site
    Munchen, Bayern 81675, Germany
  • Research Site
    Hennigsdorf, Brandenburg 16761, Germany
  • Research Site
    Marburg, Hessen 35039, Germany
  • Research Site
    Bochum, Nordrhein-Westfalen 44791, Germany
  • Research Site
    Dresden, Sachsen 1307, Germany
  • Research Site
    Hamburg, 20246, Germany
  • Research Site
    L´Hospitalet de Llobregat, Barcelona 8907, Spain
  • Research Site
    Málaga, Malaga 29010, Spain
  • Research Site
    El Palmar, Murcia 30120, Spain
  • Research Site
    Barcelona, 8035, Spain
  • Research Site
    Valencia, 46009, Spain
  • Research Site
    Valencia, 46010, Spain
09

References and documents

Publications

  • Nakamura K, Brown RA, Narayanan S, Collins DL, Arnold DL; Alzheimer's Disease Neuroimaging Initiative. Diurnal fluctuations in brain volume: Statistical analyses of MRI from large populations. Neuroimage. 2015 Sep;118:126-32. doi: 10.1016/j.neuroimage.2015.05.077. Epub 2015 Jun 3. PubMed 26049148 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2013, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2010
First posted
Feb 19, 2010
Start
Mar 2010
Primary completionActual
Nov 2011
CompletionActual
Nov 2011
Results first posted
Jan 30, 2013
Last update
Sep 19, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01071083
Lead sponsor
Biogen
Collaborators
Elan Pharmaceuticals
Responsible party
Sponsor
First posted
Feb 19, 2010
Start date
Mar 2010
Primary completion
Nov 2011
Completion
Nov 2011
Results posted
Jan 30, 2013
Last update
Sep 19, 2013
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Natalizumab · Interferon beta-1a · Methylprednisolone · Glatiramer

Start the discussion